SCHEMBL13321923

SCHEMBL13321923

CO[C@H]1OC(COS(=O)(=O)O)[C@@H](OSOOO)[C@H](O[C@@H]2OC(C(=O)O)[C@@H](O)[C@H](O)C2O)C1NC(C)=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BDNF P23560 3/20 0.54
▸ PTN P21246 2/20 0.54
▸ MDK P21741 2/20 0.54
▸ F10 P00742 6/20 0.49
▸ SERPINC1 P01008 1/20 0.40
▸ FGF2 P09038 5/20 0.39
▸ HPSE Q9Y251 2/20 0.36
▸ BMP2 P12643 2/20 0.35
▸ VEGFA P15692 2/20 0.35
▸ CXCL12 P48061 2/20 0.35
▸ SHH Q15465 2/20 0.35
▸ IFNG P01579 1/20 0.35
▸ PF4 P02776 1/20 0.35
▸ CCL2 P13500 1/20 0.35
▸ SELP P16109 1/20 0.35
▸ BMP6 P22004 1/20 0.35
▸ CCL11 P51671 1/20 0.35
▸ WNT3A P56704 1/20 0.35
▸ SELPLG Q14242 1/20 0.35
▸ LGALS3 P17931 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13321927 0.91 MDK (0.51) BDNFPTNMDKF10SERPINC1
SCHEMBL13431463 0.89 MDK (0.56) BDNFPTNMDKF10SERPINC1
SCHEMBL13431447 0.87 MDK (0.58) BDNFPTNMDKF10FGF2
SCHEMBL13596935 0.87 MDK (0.58) BDNFPTNMDKF10FGF2
SCHEMBL14414765 0.87 BDNF (0.53) BDNFPTNMDKF10FGF2
SCHEMBL14208653 0.87 BDNF (0.65) BDNFPTNMDKF10SERPINC1
SCHEMBL13596920 0.86 MDK (0.54) BDNFPTNMDKF10SERPINC1
SCHEMBL13321920 0.86 F10 (0.40) BDNFPTNMDKF10SERPINC1
SCHEMBL13130299 0.84 LGALS3 (0.42) BDNFPTNMDKF10LGALS3
SCHEMBL13596899 0.84 MDK (0.50) BDNFPTNMDKF10SERPINC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394781-B2 Disaccharides for the treatment of tendons, ligaments, and bones BIOIBERICA, S.A. (ES) 2013-03-12 — — US disclosed
US-20100129331-A1 DISACCHRIDES FOR THE TREATMENT OF TENDONS, LIGAMENTS, AND BONES BIOIBERICA, S.A. (ES) 2010-05-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100129331-A1 DISACCHRIDES FOR THE TREATMENT OF TENDONS, LIGAMENTS, AND BONES IGFBP1, FGF1, IGFBP2 BDNF 151/4885PTN 494/4885MDK 989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback